Prescription medication · PCSK9 siRNA
inclisiran
Also sold as Leqvio. Leqvio is used to lower LDL-C (bad cholesterol) in adults who have high cholesterol.
Data updated 2026-05-15
- 6,989
- FDA reportsLightly reported
- Rx
- Availability
inclisiran (Leqvio) is a prescription PCSK9 siRNA. Leqvio is used to lower LDL-C (bad cholesterol) in adults who have high cholesterol.
Leqvio is a medicine that helps lower bad cholesterol (LDL-C) in adults. It is used along with diet and exercise.
Verify with FDA → · CMS NADAC pricing →
What it does
Leqvio is used to lower LDL-C (bad cholesterol) in adults who have high cholesterol.
Common side effects
Injection site reaction (pain, redness, or rash), Joint pain, Bronchitis
Key warnings
You should not take Leqvio if you have had a serious allergic reaction to inclisiran or any of its ingredients.
The sections below are summarized in plain English from inclisiran's FDA-approved prescribing information. They describe what the official label says, and are not personal medical advice.
How It Works
Leqvio contains inclisiran, which is a small interfering RNA (siRNA). It targets a substance in the liver called PCSK9. By targeting PCSK9, Leqvio helps your body remove more LDL-C from your blood.
Side Effects (from patient reports)
Based on 6,989 FDA adverse event reports.
Most-reported reactions
Adverse reactions in FAERS for inclisiran, by number of reports
- Arthralgia
Arthralgia
740 reports
- Myalgia
Myalgia
584 reports
- Injection Site Pain
Injection Site Pain
509 reports
- Low Density Lipoprotein Increased
Low Density Lipoprotein Increased
447 reports
- Pain In Extremity
Pain In Extremity
442 reports
- Pain
Pain
370 reports
- Fatigue
Fatigue
363 reports
- Diarrhoea
Diarrhoea
326 reports
- Dyspnoea
Dyspnoea
319 reports
- Headache 259
Headache
259 reports
What this shows Bars show how often each reaction was reported, not how likely it is to happen, a report records a temporal association, never proof that the drug caused it.
Reports over time
Adverse-event reports filed for inclisiran each year to the FDA Adverse Event Reporting System (FAERS).
Year-to-year volume tracks usage, prescribing, and scrutiny, not a change in per-patient risk. Source: FDA FAERS.
Where inclisiran sits
inclisiran has more FDA adverse-event reports than 31% of the drugs FAERS tracks. A high position reflects how widely a drug is used and watched, not how dangerous it is.
Percentile across all drugs PlainMeds tracks by FAERS report volume. The dot is inclisiran; the line is the median (50th percentile).
FDA Adverse Event Report Analysis
Detailed analysis of 6,989 reports from the FDA Adverse Event Reporting System (FAERS). Reports span 2018–2025.
Total Reports
6,989
Reports Mentioning Death
190
2.7% of reports — not proof of cause
Hospitalization Reports
651
Top Indication
Product Used For Unknown Indication
Gender Distribution
Age Distribution
Most Reported Adverse Reactions (FAERS)
| # | Reaction | Reports |
|---|---|---|
| 1 | ARTHRALGIA | 740 |
| 2 | MYALGIA | 584 |
| 3 | INJECTION SITE PAIN | 509 |
| 4 | LOW DENSITY LIPOPROTEIN INCREASED | 447 |
| 5 | PAIN IN EXTREMITY | 442 |
| 6 | PAIN | 370 |
| 7 | FATIGUE | 363 |
| 9 | DIARRHOEA | 326 |
| 10 | DYSPNOEA | 319 |
| 11 | HEADACHE | 259 |
| 12 | RASH | 241 |
| 13 | MUSCLE SPASMS | 221 |
| 14 | PRODUCT STORAGE ERROR | 210 |
| 15 | DIZZINESS | 202 |
| 16 | BACK PAIN | 194 |
Reactions in Death Reports
Reactions in Hospitalization Reports
Source: FDA FAERS (Adverse Event Reporting System) Reports are voluntary and do not establish causation
Serious Warnings
You should not take Leqvio if you have had a serious allergic reaction to inclisiran or any of its ingredients. Serious allergic reactions can include swelling of the face, lips, tongue, or throat (angioedema).
Common Questions
How quickly will Leqvio lower my cholesterol?
Can I inject Leqvio myself?
Where on my body will the injection be given?
What should the medicine look like?
What if I see particles in the medicine?
Will I need to continue my diet and exercise plan while taking Leqvio?
How often will I need to get Leqvio injections?
What if I have a skin condition at the injection site?
Can I take Leqvio if I am breastfeeding?
Will my doctor check my cholesterol levels while I'm on this medication?
What are the common side effects of inclisiran?
What drug class is inclisiran?
What pregnancy or breastfeeding source fields are listed for inclisiran?
Related Medications in PCSK9 siRNA
Other drugs grouped near inclisiran - same-class peers and common alternatives.
alirocumab
Praluent
Praluent is a medicine that can lower cholesterol.
Compare with inclisiran →
atorvastatin
Lipitor
Atorvastatin is a drug that lowers cholesterol and reduces the risk of heart problems and stroke.
Compare with inclisiran →
bempedoic acid
Nexletol
Compare with inclisiran →
bempedoic acid/ezetimibe
Nexlizet
Nexlizet is a combination medicine that helps lower cholesterol.
Compare with inclisiran →
cholestyramine
Questran
Cholestyramine is a medicine that helps lower high cholesterol levels in your blood.
Compare with inclisiran →
Compare beyond drug class
Nationwide peers by FAERS volume & death-report share
Two PlainMeds-derived comparison paths for inclisiran: nearest FDA FAERS report volume and nearest death-report share among drugs with at least 1,000 logged reports, excluding same-class neighbors listed above. Counts reflect reporting volume, not proven individual harm.
Similar FAERS report volume
Nearest drugs by total FAERS reports. This record: 6,989.
Similar death-report share
Nearest drugs by FAERS death-report share. This record: 2.72%.
- bimatoprost Δ 0.01 pts · 28,128 reports · Prostaglandin Analog (Ophthalmic) 2.71%death share
- lurasidone Δ 0.03 pts · 20,544 reports · Atypical Antipsychotic 2.75%death share
- fexofenadine Δ 0.05 pts · 19,831 reports · Second-Generation Antihistamine 2.77%death share
- etanercept Δ 0.07 pts · 591,578 reports · TNF-Alpha Inhibitor (Biologic) 2.79%death share
Medication Guides
Understanding Drug Interactions
How CYP450 enzymes, inhibitors, and inducers affect your medications
Generic vs Brand Name Drugs
FDA requirements, cost savings, and when the difference matters
Narrow Therapeutic Index Drugs
FDA bioequivalence and label-record context for narrow therapeutic index medicines
Common Drug Interactions
Dangerous medication combinations and how to protect yourself
Save on inclisiran
Compare prices and find discounts at pharmacies near you. Free coupons can save up to 80% on prescriptions.
Disclosure: This link may earn us a commission at no extra cost to you. See our terms.
What the FDA Data Shows for inclisiran
The FDA label for inclisiran (sold under brand names such as Leqvio) classifies it as a prescription-only medication in the PCSK9 siRNA class. Leqvio is used to lower LDL-C (bad cholesterol) in adults who have high cholesterol. Official labeling lists 3 commonly reported side effects, including Injection site reaction (pain, redness, or rash), Joint pain, Bronchitis.
Post-market surveillance from the FDA Adverse Event Reporting System (FAERS) captures real-world experience. For this drug, FAERS contains 6,989 voluntary reports. Interaction data is drawn directly from FDA-approved prescribing information. Acquisition-cost data is surveyed weekly by CMS and updated as manufacturers report changes.
Report counts do not establish causation, a FAERS entry documents a temporal association, not proof that the drug produced the outcome. Widely prescribed medications naturally accumulate more reports than niche therapies, so raw totals must be interpreted alongside total exposure. Shortage status, recall history, and patent information are separate source-record fields. This page is a public FDA/CMS registry and does not provide medical, treatment, substitution, or medication-change directions.
Data Sources
Drug labeling: FDA Drug Labels (SPL/DailyMed). Adverse events: FDA Adverse Event Reporting System (FAERS).
FAERS reports are voluntary and do not establish causation. Drug interactions are derived from FDA labeling and clinical references. This registry does not provide medication decisions.
Last updated: July 31, 2025
PlainMeds is rendered directly from FDA openFDA/FAERS extracts, DailyMed labels, and CMS drug-pricing files, no number is typed in by an editor. FAERS counts, recalls, shortages, and price figures on this page are queried live from those federal extracts. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-05-15. Primary sources: openFDA / FAERS, DailyMed and CMS Part B ASP.
Read our methodology - how this data is sourced, computed, and verified.
Data currency: FDA FAERS adverse-event reports through 2025, CMS NADAC acquisition-cost pricing effective December 2024, compiled from the source snapshot dated . See our methodology for per-source dates and refresh cadence. Spot a figure that looks wrong? Report a data issue.
All federal data sources used on this page
- FDA Orange Book - approved drug products with therapeutic equivalence. accessdata.fda.gov/cder/ob
- FDA DailyMed - NIH-hosted drug labeling for FDA-approved meds. dailymed.nlm.nih.gov
- FDA Adverse Event Reporting System (FAERS) - post-marketing safety surveillance. fda.gov/drugs/faers
- NLM RxNorm - standardized clinical drug nomenclature. nlm.nih.gov/research/umls/rxnorm
- CMS Medicare Part B Drug Average Sales Price Files - federal drug pricing data. cms.gov/medicare/part-b-drugs/asp
- FDA Drug Shortages Database - current and resolved drug shortage tracking. accessdata.fda.gov/drugshortages